The Importance of Transurethral Resection of Bladder Tumor in the Management of Nonmuscle Invasive Bladder Cancer: A Systematic Review of Novel Technologies

Abstract

Recent advances in transurethral bladder tumor resection should aid its diagnostic accuracy, reduce recurrences, decrease complications and reduce the cost of management of nonmuscle invasive bladder cancer. Urologists should incorporate these evidence-based strategies into current guideline recommendations to improve patient outcomes following transurethral resection of bladder tumor in everyday practice.

Impact of a teaching program on outcome quality of white light transurethral resection for bladder tumor: A cohort study

“…[11,12] The expected results of TURBT include the complete eradication and an adequate pathological staging and grading of NMIBC. The procedure is generally assumed to be technically easy to complete after a short learning curve and is frequently proposed to residents as the first surgical approach during their urologic training.…”

Comparative Tissue Proteomics of Microdissected Specimens Reveals Novel Candidate Biomarkers of Bladder Cancer

“…All captured cells were dissolved in 100 l of extraction buffer (0.5% RapiGest; Waters, Milford, MA) in 0.05 M triethylammonium bicarbonate buffer (TEAB; Sigma-Aldrich, Inc., St. Louis, MO) by vortexing at room temperature for 10 min. The concentration of protein in extracts was measured using the Bradford assay (Bio-Rad), and the protein profiles were further inspected by 1 The abbreviations used are: LCM, laser capture microdissection; CA2, carbonic anhydrase 2; HgEs, high grade and early stage; HgAs, high grade and advanced stage; iTRAQ, isobaric tags for relative and absolute quantitation; LC-MS/MS, liquid chromatography tandem mass spectrometry; LgEs, low grade and early stage; PGK1, Phosphoglycerate kinase 1; RBC, red blood cell; SDS-PAGE, sodium dodecyl sulfate-polyacrylamide gel electrophoresis; SFN, 14-3-3sig-ma; SLC3A2, 4F2 cell-surface antigen heavy chain; STMN1, stathmin; TPP, Trans-Proteomic Pipeline; TXN, thioredoxin; UTI, urinary tract infection; WBC, white blood cell. sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and silver staining.…”

“…ELISA results revealed significantly increased urinary levels of both STMN1 and TAGLN2 in bladder cancer subgroups compared with control groups. In comparisons with agematched hernia urine specimens, urinary TAGLN2 in bladder cancer samples showed the largest fold change Bladder cancer is potentially lethal and is the most costly urologic malignancy to manage (1). Risk factors associated with bladder cancer include carcinogens in tobacco smoke and environmental and/or occupational exposure to chemical compounds.…”

“…In the current study, we searched for potential bladder cancer biomarkers by profiling proteomic changes in tissue specimens of bladder tumors using a strategy combining laser capture microdissection (LCM) 1 , isobaric tags for relative and absolute quantitation labeling (iTRAQ), and linear trap quadrupole-Orbitrap tandem mass spectrometry (LTQOrbitrap MS/MS) analysis. Cancerous cells and adjacent nontumorous cells were obtained by LCM from four pairs of surgically resected primary bladder cancer tissue specimens for two batches of four-plex iTRAQ experiments.…”

The effect of surgical duration of transurethral resection of bladder tumors on postoperative complications: An analysis of ACS NSQIP data

“…As nonmuscle-invasive tumors recur greater than 50% of the time and several indications exist for re-resection [2], TURBT is a commonly performed procedure for urologists. Though new modalities for therapy are under development [3], including laser ablation [4], monopolar or bipolar resection remains the gold standard.…”